Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02905903 · ClinicalTrials.gov registry record · NA

An In Vivo Model for Postinflammatory Hyperpigmentation

A NA study of Post-inflammatory Hyperpigmentation, sponsored by Henry Ford Health System.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02905903 is a NA study of Post-inflammatory Hyperpigmentation that has completed, run by Henry Ford Health System. The registered enrollment target is 30 participants, above the 18-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02905903, a NA study of Post-inflammatory Hyperpigmentation, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the treatment of PIH. In this second phase of the study, the investigators would like to determine if a lower concentration of TCA-induced PIH is comparable to acne-induced PIH.

Interventions

  • DRUG Tricholoacetic Acid (TCA)

Study Locations (1)

Michigan

  • Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, - Detroit

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-02-14
Est. Completion 2019-06-21
Phase NA

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT02905903

The ClinicalTrials.gov registry entry for NCT02905903 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 18-participant average among 3 other Post-inflammatory Hyperpigmentation trials with a reported enrollment target (67% higher). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-inflammatory Hyperpigmentation appearing as the primary indexed condition, and to 1 intervention - of which Tricholoacetic Acid (TCA) is the first listed.

NCT02905903 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT02905903 about?

NCT02905903 is a clinical study titled "An In Vivo Model for Postinflammatory Hyperpigmentation". Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the...

What is the current status of trial NCT02905903?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-02-14. Estimated completion is 2019-06-21.

What conditions does trial NCT02905903 study?

This clinical trial studies the following conditions: Post-inflammatory Hyperpigmentation.

What interventions are being tested in trial NCT02905903?

The interventions under investigation include: Tricholoacetic Acid (TCA) (DRUG).

Who is sponsoring clinical trial NCT02905903?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02905903 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-inflammatory Hyperpigmentation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.